For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Denali Therapeutics Inc.

USPTO Granted Patents = 52

EPO Patents = 11

Trademarks = 3

Forward Citations = 129

Loading Chart...

Loading Chart...

71 inventors (with patents filed for the assignee):

Jianwen A Feng (27 out of 33 patents)

Javier De Vicente Fidalgo (26 out of 34 patents)

Anthony A Estrada (26 out of 52 patents)

4. Zachary Kevin Sweeney (24 out of 75 patents)

5. Brian M Fox (16 out of 25 patents)

6. Joseph P Lyssikatos (13 out of 139 patents)

7. Maksim Osipov (12 out of 24 patents)

8. Adam P Silverman (10 out of 12 patents)

9. Mihalis S Kariolis (10 out of 10 patents)

10. Mark S Dennis (9 out of 97 patents)

11. Anantha R Sudhakar (9 out of 47 patents)

12. Colin Philip Leslie (8 out of 13 patents)

13. Travis Remarchuk (7 out of 15 patents)

14. Arun Thottumkara (7 out of 7 patents)

15. Ankita Srivastava (7 out of 7 patents)

Core Competencies:

Fusion Proteins

LRRK2 Inhibitors

Anti-TREM2 Antibodies

Transferrin Receptor Binding Polypeptides

Kinase Inhibitors

Engineered Polypeptides

Progranulin Variants

Anti-BACE1 Antibodies

Eukaryotic Initiation Factor Modulators

Pyrimidinyl Compounds

Transgenic Models

Receptor Interacting Protein Kinase Inhibitors

52 patents: Sort by Forward Citations

1. 12497387 - Process for the preparation of pyrimidinyl-4-aminopyrazole compounds (2025-12-16),

2. 12378540 - Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof (2025-08-05),

3. 12358928 - Compounds, compositions and methods (2025-07-15),

4. 12358896 - LRRK2 inhibitors and methods of making and using thereof (2025-07-15),

5. 12240902 - Anti-TREM2 antibodies and methods of use thereof (2025-03-04),

6. 12180211 - Compounds, compositions and methods (2024-12-31),

7. 12162948 - Methods of engineering transferrin receptor binding polypeptides (2024-12-10),

8. 12139478 - Compounds, compositions and methods (2024-11-12),

9. 12129263 - Kinase inhibitors and uses thereof (2024-10-29),

10. 12091392 - Compounds, compositions and methods (2024-09-17),

11. 11999750 - Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide (2024-06-04),

12. 11958840 - Compounds, compositions and methods (2024-04-16),

13. 11912778 - Methods of engineering transferrin receptor binding polypeptides (2024-02-27),

14. 11884944 - Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof (2024-01-30),

15. 11866742 - Fusion proteins comprising enzyme replacement therapy enzymes (2024-01-09),

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases. With a multidisciplinary approach, Denali combines expertise in neuroscience, protein homeostasis, and blood-brain barrier to target the underlying causes of various neurodegenerative disorders. The company leverages its diverse portfolio of therapeutic programs to address conditions like Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and more.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

52 Patents

#24 in South San Francisco, CA

#1,546 in California

#6,542 in US

#13,160 in the World

South San Francisco, CA, United States of America

Denali Therapeutics Inc.

Forward Citations = 129

71 inventors:

Jianwen A Feng (27 out of 33 patents)

Javier De Vicente Fidalgo (26 out of 34 patents)

Anthony A Estrada (26 out of 52 patents)

4. Zachary Kevin Sweeney (24 out of 75 patents)

5. Brian M Fox (16 out of 25 patents)

Please report any incorrect information to support@idiyas.com

Loading…